IP Library Granted Patent US 10,617,687
Granted Patent B2
US 10,617,687 · App. 15/178,720 · Granted Apr 14, 2020

Fluorescent pyrazine derivatives and methods of using the same in assessing renal function

Inventors: Raghavan Rajagopalan (Solon, OH); Richard B. Dorshow (St. Louis, MO); William L. Neumann (St. Louis, MO); Dennis A. Moore (St. Louis, MO)
Assignee: MediBeacon Inc.
A61K31/4965A61K49/0004A61K49/0021A61K49/0052C07D241/20C07D241/26C07D241/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,617,687
App. No.
15/178,720
Granted
Apr 14, 2020
Kind
B2
Abstract

The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X 1 to X 4 of Formulas I and II may be characterized as electron withdrawing groups, while Y 1 to Y 4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.

Claims (33)

1. A compound of Formula I wherein:

each of X 1 and X 2 is independently selected from the group consisting of —CN, —CO 2 R 1 , —CONR 2 R 3 , —COR 4 , —SOR 5 , —SO 2 R 6 , —SO 2 OR 7 and —PO 3 R 8 R 9 ;

each of Y 1 and Y 2 is independently selected from the group consisting of —OR 10 , −SR 11 , and

Z 1 is selected from the group consisting of a direct bond, —CR 16 R 17 —, —O—, —NR 18 —, —NCOR 19 —, —S—, —SO— and —SO 2 —;

each of R 1 to R 9 , and R 16 to R 19 is independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH 2 ) 2 —O—(CH 2 ) 2 —O) a —R 40 , C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, —(CH 2 ) a OH, —(CH 2 ) a CO 2 H, —(CH 2 ) a SO 3 H, —(CH 2 ) a SO 3 − , —(CH 2 ) a OSO 3 H, —(CH 2 ) a OSO 3 − , —(CH 2 ) a NHSO 3 H, —(CH 2 ) a NHSO 3 − , —(CH 2 ) a PO 3 H 2 , —(CH 2 ) a PO 3 H − , —(CH 2 ) a PO 3 − , —(CH 2 ) a OPO 3 H 2 , —(CH 2 ) a OPO 3 H − and —(CH 2 ) a OPO 3 ;

R 10 is selected from the group consisting of C3-C6 polyhydroxylated alkyl, —((CH 2 ) 2 —O—(CH 2 ) 2 —O) a —R 40 , C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, —(CH 2 ) a OH, —(CH 2 ) a CO 2 H, —(CH 2 ) a SO 3 H, —(CH 2 ) a SO 3 − , —(CH 2 ) a OSO 3 H, —(CH 2 ) a OSO 3 − , —(CH 2 ) a NHSO 3 H, —(CH 2 ) a NHSO 3 − , —(CH 2 ) a PO 3 H 2 , —(CH 2 ) a PO 3 H − , —(CH 2 ) a PO 3 − , —(CH 2 ) a OPO 3 H 2 , —(CH 2 ) a OPO 3 H − and —(CH 2 ) a OPO 3 ;

R 40 is selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, —(CH 2 ) a OH, —(CH 2 ) a CO 2 H, —(CH 2 ) a SO 3 H, —(CH 2 ) a SO 3 − , —(CH 2 ) a OSO 3 H, —(CH 2 ) a OSO 3 − , —(CH 2 ) a NHSO 3 H, —(CH 2 ) a NHSO 3 − , —(CH 2 ) a PO 3 H 2 , —(CH 2 ) a PO 3 H − , —(CH 2 ) a PO 3 − , —(CH 2 ) a OPO 3 H 2 , —(CH 2 ) a OPO 3 H − and —(CH 2 ) a OPO 3 ; and

each of a, m and n range from 1 to 6;

with the proviso that if:

each of X 1 and X 2 is independently —CN, —CO 2 R 1 or —CONR 2 R 3 ;

each of Y 1 and Y 2 is

and

Z 1 is a direct bond, then:

each of R 1 , R 2 , and R 3 , are independently not hydrogen, C1-C10 alkyl or C5-C10 aryl; and

the sum of m and n is not 4 or 5.

2. The compound of claim 1 wherein:

each of X 1 and X 2 is independently selected from the group consisting of —CN, —CO 2 R 1 and —CONR 2 R 3 ;

each of Y 1 and Y 2 is

each of R 1 , R 2 , and R 3 is independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH 2 ) 2 —O—(CH 2 ) 2 —O) a —R 40 , C5-C10 heteroaryl —(CH 2 ) a OH, —(CH 2 ) a CO 2 H, —(CH 2 ) a SO 3 H and —(CH 2 ) a SO 3 − ;

each of R 16 to R 19 is independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH 2 ) 2 —O—(CH 2 ) 2 —O) a —R 40 , C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, —(CH 2 ) a OH, —(CH 2 ) a CO 2 H, —(CH 2 ) a SO 3 H and —(CH 2 ) a SO 3 − ;

m is 1 or 2; and

n is 1.

3. The compound of claim 2 wherein:

each of X 1 and X 2 is —CN;

Z 1 is selected from the group consisting of a direct bond, —O—, —NR 18 —, —NCOR 19 —, —S—, —SO— and —SO 2 —;

each of R 18 and R 19 is independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH 2 ) 2 —O—(CH 2 ) 2 —O) a —R 40 , C1-C10 alkyl, —(CH 2 ) a OH, —(CH 2 ) a CO 2 H, —(CH 2 ) a SO 3 H and —(CH 2 ) a SO 3 − ;

m is 1 or 2; and

n is 1.

4. The compound of claim 2 wherein:

each of X 1 and X 2 is —CO 2 R 1 ;

Z 1 is selected from the group consisting of a direct bond, —O—, —NR 18 —, —NCOR 19 —, —S—, —SO— and —SO 2 —;

R 1 is hydrogen; and

each of R 18 and R 19 is independently selected from the group consisting of hydrogen, C3-C6 polyhydroxylated alkyl, —((CH 2 ) 2 —O—(CH 2 ) 2 —O) a —R 40 , C1-C10 alkyl, —(CH 2 ) a OH, —(CH 2 ) a CO 2 H, —(CH 2 ) a SO 3 H and —(CH 2 ) a SO 3 − .

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 043310 FRAME: 0269. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 20, 2017
From: RAJAGOPALAN, RAGHAVAN; DORSHOW, RICHARD B.; NEUMANN, WILLIAM L.; MOORE, DENNIS A.
To: MEDIBEACON, LLC
Reel/Frame 044242/0698 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2017
From: RAJAGOPALAN, RAGHAVAN; DORSHOW, RICHARD B.; NEUMANN, WILLIAM L.; MOORE, DENNIS A.
To: MEDIBEACON DEVELOPMENT, LLC
Reel/Frame 043310/0269 →
CHANGE OF NAME Recorded Aug 16, 2017
From: MEDIBEACON LLC
To: MEDIBEACON INC.
Reel/Frame 043919/0039 →
Continuity (4)
Continuation 14047733 · Oct 7, 2013
Division 11721186
Provisional Application 60638611 · Dec 23, 2004
Related Publication 20160280665A1 · Sep 29, 2016